Drug search by name

Aminosalicylate sodium and Hepatotoxicity

Generic Name: aminosalicylic acid
Dosage Forms: n.a.
Other Brand Names: Paser

Result of checking the interaction of drug Aminosalicylate sodium and disease Hepatotoxicity for safety when used together.

Check result:

Aminosalicylate sodium <> Hepatotoxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Aminosalicylic acid is decarboxylated in stomach acid to an inactive metabolite that is hepatotoxic. In a retrospective study of nearly 7,500 patients treated with older formulations of the drug, hepatitis developed in 0.5% of them. Premonitory symptoms (most often rash, followed by fever and, much less frequently, by GI disturbances such as anorexia, diarrhea, or nausea) usually occurred within the first 3 months of therapy and preceded jaundice by a few days to several weeks. Although the currently marketed granule formulation of aminosalicylic acid contains an acid- resistant coating that protects against degradation in the stomach, the drug should nevertheless be used with caution in patients with liver disease. These patients should be followed particularly closely for the first three months, and therapy promptly discontinued if liver disease becomes worse or premonitory symptoms appear. The drug should be administered sprinkled in an acidic food (e.g., apple sauce, yogurt) or suspended in a fruit juice to prevent dissolution of the coating, which occurs under neutral conditions.

References: